| Home > Publications Database > Activation of the medial preoptic area (MPOA) ameliorates loss of maternal behavior in a Shank2 mouse model for autism. > print |
| 001 | 164199 | ||
| 005 | 20240619121039.0 | ||
| 024 | 7 | _ | |a 10.15252/embj.2019104267 |2 doi |
| 024 | 7 | _ | |a pmid:33491217 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC7917557 |2 pmc |
| 024 | 7 | _ | |a 0261-4189 |2 ISSN |
| 024 | 7 | _ | |a 1460-2075 |2 ISSN |
| 024 | 7 | _ | |a altmetric:98840631 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-00855 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Grabrucker, Stefanie |b 0 |
| 245 | _ | _ | |a Activation of the medial preoptic area (MPOA) ameliorates loss of maternal behavior in a Shank2 mouse model for autism. |
| 260 | _ | _ | |a Hoboken, NJ [u.a.] |c 2021 |b Wiley |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1718784905_8364 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Impairments in social relationships and awareness are features observed in autism spectrum disorders (ASDs). However, the underlying mechanisms remain poorly understood. Shank2 is a high-confidence ASD candidate gene and localizes primarily to postsynaptic densities (PSDs) of excitatory synapses in the central nervous system (CNS). We show here that loss of Shank2 in mice leads to a lack of social attachment and bonding behavior towards pubs independent of hormonal, cognitive, or sensitive deficits. Shank2-/- mice display functional changes in nuclei of the social attachment circuit that were most prominent in the medial preoptic area (MPOA) of the hypothalamus. Selective enhancement of MPOA activity by DREADD technology re-established social bonding behavior in Shank2-/- mice, providing evidence that the identified circuit might be crucial for explaining how social deficits in ASD can arise. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 650 | _ | 7 | |a SHANK3 |2 Other |
| 650 | _ | 7 | |a autism spectrum disorders |2 Other |
| 650 | _ | 7 | |a bonding |2 Other |
| 650 | _ | 7 | |a social behavior |2 Other |
| 650 | _ | 7 | |a synapse |2 Other |
| 650 | _ | 7 | |a DREADD agonist compound 21 |2 NLM Chemicals |
| 650 | _ | 7 | |a Nerve Tissue Proteins |2 NLM Chemicals |
| 650 | _ | 7 | |a Piperazines |2 NLM Chemicals |
| 650 | _ | 7 | |a Shank2 protein, mouse |2 NLM Chemicals |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Autistic Disorder: drug therapy |2 MeSH |
| 650 | _ | 2 | |a Autistic Disorder: etiology |2 MeSH |
| 650 | _ | 2 | |a Autistic Disorder: metabolism |2 MeSH |
| 650 | _ | 2 | |a Autistic Disorder: pathology |2 MeSH |
| 650 | _ | 2 | |a Disease Models, Animal |2 MeSH |
| 650 | _ | 2 | |a Female |2 MeSH |
| 650 | _ | 2 | |a Interpersonal Relations |2 MeSH |
| 650 | _ | 2 | |a Male |2 MeSH |
| 650 | _ | 2 | |a Maternal Behavior: drug effects |2 MeSH |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Mice, Inbred C57BL |2 MeSH |
| 650 | _ | 2 | |a Mice, Knockout |2 MeSH |
| 650 | _ | 2 | |a Nerve Tissue Proteins: physiology |2 MeSH |
| 650 | _ | 2 | |a Piperazines: pharmacology |2 MeSH |
| 650 | _ | 2 | |a Preoptic Area: drug effects |2 MeSH |
| 650 | _ | 2 | |a Preoptic Area: metabolism |2 MeSH |
| 650 | _ | 2 | |a Preoptic Area: pathology |2 MeSH |
| 650 | _ | 2 | |a Synapses |2 MeSH |
| 700 | 1 | _ | |a Pagano, Jessica |b 1 |
| 700 | 1 | _ | |a Schweizer, Johanna |0 0000-0001-5058-6693 |b 2 |
| 700 | 1 | _ | |a Urrutia-Ruiz, Carolina |b 3 |
| 700 | 1 | _ | |a Schön, Michael |b 4 |
| 700 | 1 | _ | |a Thome, Kevin |b 5 |
| 700 | 1 | _ | |a Ehret, Günter |b 6 |
| 700 | 1 | _ | |a Grabrucker, Andreas M |b 7 |
| 700 | 1 | _ | |a Zhang, Rong |b 8 |
| 700 | 1 | _ | |a Hengerer, Bastian |b 9 |
| 700 | 1 | _ | |a Bockmann, Jürgen |b 10 |
| 700 | 1 | _ | |a Verpelli, Chiara |0 P:(DE-2719)9000803 |b 11 |u dzne |
| 700 | 1 | _ | |a Sala, Carlo |0 P:(DE-2719)9000735 |b 12 |u dzne |
| 700 | 1 | _ | |a Böckers, Tobias |0 P:(DE-2719)2812855 |b 13 |e Last author |u dzne |
| 773 | _ | _ | |a 10.15252/embj.2019104267 |g Vol. 40, no. 5 |0 PERI:(DE-600)1467419-1 |n 5 |p e104267 |t The EMBO journal |v 40 |y 2021 |x 0261-4189 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/164199/files/DZNE-2022-00855.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/164199/files/DZNE-2022-00855.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:164199 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 11 |6 P:(DE-2719)9000803 |
| 910 | 1 | _ | |a External Institute |0 I:(DE-HGF)0 |k Extern |b 12 |6 P:(DE-2719)9000735 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2812855 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 914 | 1 | _ | |y 2021 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-12 |
| 915 | _ | _ | |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0 |0 LIC:(DE-HGF)CCBYNCND4 |2 HGFVOC |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EMBO J : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a IF >= 10 |0 StatID:(DE-HGF)9910 |2 StatID |b EMBO J : 2021 |d 2022-11-12 |
| 915 | _ | _ | |a DEAL Wiley |0 StatID:(DE-HGF)3001 |2 StatID |d 2021-01-30 |w ger |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-12 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-12 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2021-01-30 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-12 |
| 920 | 1 | _ | |0 I:(DE-2719)1910002 |k AG Böckers |l Translational Protein Biochemistry |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1910002 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|